Manufacturer record
Concord Drugs Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
3 batches manufactured by Concord Drugs Ltd (Telangana) were declared Not of Standard Quality between September 2020 and August 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: PRD2516, Prednisolone Tablets IP (exp Nov 2027). RDTL, Guwahati (CDSCO lab) found it not of standard quality: The sample is not of standard quality for the reason stated under Description of the tablets. Listed in the August 2026 alert.
Records by type
3 records linked to Concord Drugs Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Prednisolone Tablets IP | Batch PRD2516Mfg Dec 2025 · Exp Nov 2027 | The sample is not of standard quality for the reason stated under Description of the tablets.Description | RDTL, GuwahatiCDSCO lab | Aug 2026 |
| Moovrun tablets Diclofenac Sodium and Paracetamol tablets | Batch DFP- 2403Mfg Jan 2024 · Exp Dec 2025 | MISBRANDED DRUG The drug product Diclofenac sodium and Paracetamol tablets is offcially included in the current edition of Indian Pharmacopoeia IP 2022 and as required as per second schedule of the Drugs and Cosmetics Act, 1940 the said Product shall comply with the standards set out in the Indian Pharmacopoeia. But the designation IP in conjunction with the offcial title Diclofenac sodium and Paracetamol tablets on the label of the drug product was not mentioned as an indication that the drug product purports to comply with the IP satadards. Hence the drug product shall deemed to be MISBRANDED DRUG as per section 17 of Drugs and Cosmetics Act, 1940 as it is not labelled in the prescribed Manner.Misbranded | State Lab Drugs Control Laboratory, TelanganaState lab | Feb 2025 |
| ROOTCAL ((Calcium Citrate Malate & Vitamin D3 Tablets) | Batch RTC-1910Mfg Oct 2019 · Exp Sep 2021 | Disintegration and Assay of Vitamin D3Assay | CDL KolkataCDSCO lab | Sep 2020 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.